Intravenous tissue-type plasminogen activator for the treament of acute cerebral ischemia;Tratamiento intravenoso con activador del plasminógeno tisular en la isquemia cerebral aguda

Medicina Clinica

Volumn 120, Issue 1, 2003, Pages 1-5

  Dávalos, Antoni ^a   Álvarez Sabín, José ^b   Martí Vilalta, Lluís ^c   Castillo, José ^d  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

Cerebral infarction; Registry; Thrombolisis; Tissue plasminogen activator; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL OBSERVATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG INFUSION; DRUG SAFETY; DRUG USE; FATALITY; FEMALE; HOSPITAL CARE; HOSPITAL DEPARTMENT; HUMAN; INDEPENDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MEDICAL SPECIALIST; MORTALITY; NEUROLOGY; PATIENT MONITORING; PROSPECTIVE STUDY; RATING SCALE; RISK ASSESSMENT; SPAIN; SYMPTOM; TIME; TREATMENT OUTCOME;

EID: 0037452293     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042004     Document Type: Article

References (37)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
2. Wardlaw JM, Del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke (Cochrane Review). En: The Cochrane Library, Issue 2, 2002. Oxford: Update Software.
3. Brott TG, Kaste M, Albers GW. Analysis of NINDS, ECASS I and ECASS II and ATLANTIS Data Sets. Actas 27th International Stroke Conference; 2002 febrero 7; San Antonio, Texas.
4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, Von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995; 274:1017-25.
5. Hacke W, Kaste M, Fieschi C, Von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
6. Clark WM, Albers GW, Madden KP. Hamilton S, for the Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators. The rt-PA (Alteplase) 0- to 6-hour acute stroke trial, Part A (A0267g): results of a double-blind, placebo-controlled, multicenter study. Stroke 2000;31:811-6.
7. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, for the ATLANTIS Study Investigators. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial. JAMA 1999;282:2019-26.
8. Alberts MJ. TPA in acute ischemic stroke. United States experience and issues for the future. Neurology 1998;51(Suppl 3):53-5.
9. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke. The standard treatment with alteplase to reverse stroke (STARS) study. JAMA 2000;283:1145-50.
10. Grond M, Stenzel C, Schmülling S, Rudolf J, Nevelling M, Lechleuthner A, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544-9.
11. Buchan AM, Barber PA, Newcommon N, Karbalai HG, Demchuck AM, Hoyte KM, et al. Effectiveness of t-PA in acute ischemic stroke. Outcome relates to appropriateness. Neurology 2000; 54:679-84.
12. Grotta JC, Alexadrov AV, Burgin WS, Long M, El-Mitwalli A, Campbell M, et al. Intravenous t-PA for ischemic stroke patients: Houston experience 1996-2000. Stroke 2001;32:323.
13. Hill MD, Buchan AM. The Canadian Activase for Stroke Effectiveness Study (CASES): interim results. Stroke 2001;32:323.
14. Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke. The Cleveland area experience. JAMA 2000;283:1151-8.
15. Tanne D, Bates VE, Verro P, Kasner SE, Binder JR, Patel SC, et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. Neurology 1999; 53:424-7.
16. Chapman KM, Woolfenden AR, Graeb D, Johnston DCC, Beckman J, Schultzer M, et al. Intravenous tissue plasminogen activator for acute ischemic stroke. A Canadian hospital's experience. Stroke 2000;31:2920-4.
17. Wang DZ, Rose JA, Honings DS, Garwacki D, Milbrandt JC, for the OSF Stroke Team. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience. Stroke 2000; 31:77-81.
18. López-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurrú C, Biller J. Protocol violations in community-based rtPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001;32:12-6.
19. Adams HP, Brott TG, Furlan AJ, Gómez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council. American Heart Association. Stroke 1996;27:1711-8.
20. Quality Standards Subcommittee of the American Academy of Neurology: practice advisory: thrombolytic therapy for acute ischemic stroke-summary statement. Neurology 1992;42:289-98.
21. European Stroke Initiative. EUSI recommendations for stroke management. Cerebrovasc Dis 2000;10:335-51.
22. Lyden P, Brott T, Tilley B, Welch KMA, Mascha EJ, Levine S, et al. Improved reliability of the NIH Stroke Scale using video training. Stroke 1994;25:2220-6.
23. Burgin WS, Malkoff M, Felberg RA, Demchuk AM, Christou I, Grotta JC, et al. Transcranial Doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke 2000;31:1128-32.
24. Fiorelli M, Bastianello S, Von Kummer R, Del Zoppo GJ, Larrue V, Lesaffre E, et al. Hemorrhagic transformation within 36 hours of cerebral infarct. Stroke 1999;30:2280-4.
25. Berger C, Fiorelli M, Steiner T, Schäbitz W-R, Bozzao L, Bluhmki E, et al. Hemorrhagic transformation of ischemic brain tissue. Asymptomatic or symptomatic? Stroke 2001;32:1330-5.
26. Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J, for the ECASS Group. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke 1999;30:2631-6.
27. Wahlgren NG, Davalos A, Grond M, Fieschi C, Hacke W, Kaste M, et al. The SITS Monitoring Study (SITS-MOST): is routine use of t-PA within 3 hous after acute ischemic stroke as beneficial as in randomised controlled trials? Cerebrovasc Dis 2002;13(Suppl 3):81.
28. Larrue V, Von Kummer R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. Stroke 2001;32:438-41.
29. Ringleb PA, Schellinger PD, Schranz C, Hacke W. Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful? Stroke 2002;33:1437-41.
30. Parsons MW, Barber PA, Chalk J, Darby DG, Rose S, Desmond PM, et al. Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002;51:28-37.
31. Alexandrov AV, Demchuk Am, Felberg RA, Christou I, Barber PA, Burgin WS, et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial Doppler monitoring. Stroke 2000;31:610-4.
32. Christou I, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, et al. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovary from ischemic stroke. Stroke 2000;31:1812-6.
33. Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy. Circulation 2001;103:2897-902.
34. Molina CA, Montaner J, Abilleira S, Arenillas JF, Ribó M, Huertas R, et al. Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke. A case-control study. Stroke 2001;32:2821-7.
35. Castellanos M, Serena J, Dávalos A. Recanalización de la arteria cerebral media evaluada por Doppler transcraneal y recuperación clacinica precoz durante la infusión de tratamiento trombolitico. Neurología 2001;16:51-3.
36. Cintas P, Le Traon AP, Larrue V. High rate of recanalization of middle cerebral artery occlusion during 2-MHz transcranial color-coded Doppler continuous monitoring without thrombolytic drug. Stroke 2002;33:626-8.
37. Mostacero E, Santos S, Dávalos A, Fil-Peralta A, Castillo J, Rebollo M, et al. Eligibility for intravenous thrombolysis in acute stroke: a multicenter prospective study. Stroke 2001;32:372.